TABLE 1.
Demographics and baseline characteristics for hospitalized patients with cancer and COVID‐19
| Hospitalized patients | |
|---|---|
| Total number, N | 2804 |
| Age in years, median (IQR) | 70 (60–79) |
| Male sex, % (N) | 54% (1504) |
| Race/ethnicity, % (N) | |
| White | 48% (1351) |
| Black | 25% (689) |
| Hispanic | 13% (368) |
| Other | 12% (345) |
| Unknown/missing | 2% (51) |
| Cancer subtype, % (N)a | |
| Solid | 74% (2079) |
| Hematologic | 24% (676) |
| Other | 2% (49) |
| Cancer status, % (N) | |
| Remission/no evidence of disease | 48% (1342) |
| Active, stable or responding | 26% (742) |
| Active, progressing or unknown | 23% (651) |
| Unknown/missing | 2% (69) |
| Cancer staging, % (N) | |
| Localized | 50% (1405) |
| Disseminated | 29% (812) |
| Unknown/missing | 21% (587) |
| Recent systemic therapy last 3 months, % (N) | |
| No | 61% (1717) |
| Yes | 36% (1021) |
| Unknown/missing | 2% (66) |
| VTE risk by cancer subtype, % (N)b | |
| Low‐risk VTE malignancy | 75% (2090) |
| High‐risk VTE malignancy | 23% (641) |
| Very high‐risk VTE malignancy | 3% (73) |
| History of VTE, % (N) | |
| No | 89% (2488) |
| Yes | 11% (297) |
| Unknown/missing | 1% (19) |
| Morbid obesity (BMI>35), % (N) | |
| No | 84% (2359) |
| Yes | 15% (429) |
| Unknown/missing | 1% (16) |
| Anticoagulant use prior to admission, % (N) | |
| No | 76% (2136) |
| Yes | 21% (584) |
| Unknown/missing | 3% (84) |
| Antiplatelet use prior to admission, % (N) | |
| No | 63% (1761) |
| Yes | 34% (949) |
| Unknown/missing | 3% (84) |
| Direct ICU admission, % (N) | |
| No | 81% (2271) |
| Yes | 16% (440) |
| Unknown/missing | 3% (93) |
| White blood cell (WBC), % (N) | |
| Within normal limit of normal | 58% (1614) |
| Below lower limit of normal | 20% (552) |
| Above higher limit of normal | 17% (468) |
| Unknown/missing | 10% (173) |
| Hemoglobin (Hb), % (N) | |
| Within normal limit of normal | 37% (1034) |
| Below lower limit of normal | 55% (1552) |
| Above higher limit of normal | 2% (45) |
| Unknown/missing | 6% (173) |
| Platelet (Plt), % (N) | |
| Within normal limit of normal | 61% (1709) |
| Below lower limit of normal | 27% (757) |
| Above higher limit of normal | 4% (125) |
| Unknown/missing | 8% (213) |
| D‐dimer (DD), % (N) | |
| Within normal limit of normal | 9% (247) |
| Above higher limit of normal | 49% (1376) |
| Not tested/not available | 37% (1034) |
| Unknown/missing | 5% (147) |
Abbreviations: BMI, body mass index; ICU, intensive care unit; IQR, interquartile range; VTE, venous thromboembolism.
a
Please refer to Table S1 for detailed cancer type breakdown.
b
Adapted from Khorana Score: very‐high risk = pancreas, stomach, esophageal; high risk = lung, ovarian, kidney, bladder, testicular, lymphoma.